For patients with advanced lung cancer whose tumors carry EGFR activating mutations, first-line treatment with erlotinib nearly tripled progression-free survival compared to a standard chemotherapy ...

Adding osimertinib to platinum-based chemotherapy may improve outcomes in patients with EGFR-mutant, advanced NSCLC who had disease progression on first-line osimertinib.

The FDA-approved Inluriyo, an oral estrogen receptor antagonist from Eli Lilly, has shown to achieve significant improvement ...